Lasa Supergenerics manufactures active pharmaceutical ingredients (APIs) primarily for the veterinary market, specializing in deworming agents and animal feed additives for global pharmaceutical companies and the poultry/dairy industries.
While management claims a moat based on 'catalyst chemistry' and process patents for Albendazole, the financial results show chronic losses and negative returns on capital, suggesting these patents do not provide durable pricing power or protection from Chinese competition. The lack of positive cash conversion contradicts the narrative of a high-barrier, proprietary business model.
Capital has been deployed into capacity expansions (Unit II and IV) and the merger of Harishree Aromatics, yet these investments have failed to generate positive returns, resulting in significant shareholder value destruction and a reliance on debt settlements.
The business likely collapsed as the insolvency proceedings initiated by the Bank of Baroda reached a terminal stage, liquidating what remained of the company's assets. The 2025 fire incident proved to be the final blow, as the lack of operational continuity and disputed insurance claims prevented any recovery of the manufacturing base. With negative net worth and no cash conversion, the company was unable to service its debt or pivot away from its failed capacity expansions, leaving shareholders with nothing but the shell of a business that never possessed the pricing power it claimed.
RichFakir rates Lasa Supergenerics Ltd's business quality as poor — 18/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Lasa Supergenerics Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →